抗疟药与系统性红斑狼疮全因及病因特异性死亡率降低相关
基于江苏狼疮数据库2446例SLE患者的前瞻性随访研究,共观察到221例死亡。与未使用者相比,HCQ或CQ使用者的全因死亡率调整风险比分别为0.49(95%CI 0.35–0.67)和0.49(95%CI 0.27–0.87)。HCQ/CQ使用时间及每日剂量与死亡率降低呈线性剂量反应关系,且与肾功能不全和其他器官受累相关死亡呈负相关。
要点
- HCQ或CQ使用与SLE患者全因死亡率降低相关,调整HR均为0.49。
- HCQ/CQ使用时间及每日剂量与死亡率降低呈线性剂量反应关系。
- HCQ/CQ与肾功能不全及其他器官受累相关死亡呈负相关,但与感染和神经精神受累死亡无显著关联。
核心结论
- 抗疟药与SLE患者较低的全因死亡风险相关,尤其是肾功能不全和其他器官受累相关死亡。
- 坚持用药和足量用药可能增强抗疟药对生存的保护效应。
研究设计与样本
- 从江苏狼疮数据库提取1999–2009年首次住院SLE患者的HCQ/CQ处方信息,并于2010年和2015年进行生存状态随访。
- 共纳入2446例SLE患者,采用Cox模型和限制性立方样条模型估计风险比及95%CI。
主要发现
- 共观察到221例死亡。
- 与未使用者相比,HCQ使用者全因死亡率调整HR为0.49(95%CI 0.35–0.67),CQ使用者为0.49(95%CI 0.27–0.87)。
- HCQ/CQ与全因死亡率的关联在合并症和器官受累等亚组中相似。
- HCQ/CQ使用时间和每日剂量均与SLE死亡率降低呈线性剂量反应关系。
- HCQ/CQ与肾功能不全相关死亡的调整HR为0.23(95%CI 0.09–0.55),与其他器官受累相关死亡的调整HR为0.25(95%CI 0.10–0.62);与感染和神经精神受累相关死亡无显著关联。
临床怎么用
- 对SLE患者可考虑使用HCQ或CQ以降低死亡风险,尤其关注肾功能不全和其他器官受累相关死亡。
- 临床应重视抗疟药的用药依从性和足量使用,以可能增强生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients. METHODS: Medical records including information on HCQ/chloroquine (CQ) prescription were extracted from Jiangsu Lupus database. The database was designed to collect data from SLE patients that first-hospitalized during 1999-2009 in Jiangsu province, China, and a follow-up for survival status was performed in 2010 and 2015. Cox and restricted cubic spline models were used to estimate the hazard ratio and 95% CI. RESULTS: We identified 221 deaths among 2446 SLE patients in total. Compared with non-users, decreased overall mortality was associated with either HCQ or CQ users, with adjusted hazard ratio (95% CI) of 0.49 (0.35, 0.67) and 0.49 (0.27, 0.87), respectively. The association between HCQ/CQ and overall mortality was similar across subgroups, such as patients with comorbidities and organ involvements. Interestingly, both the time and the daily dosage of HCQ/CQ use were related to decreased mortality of SLE in a linear dose-response relationship. In cause specific analyses, HCQ/CQ was inversely associated with death from renal insufficiency and other organ (cardiopulmonary, gastrointestinal and haematological) involvements, with adjusted hazard ratio (95% CI) of 0.23 (0.09, 0.55) and 0.25 (0.10, 0.62), respectively, yet it was not significantly associated with mortality from infection and neuropsychiatric involvements. CONCLUSION: Antimalarial drugs were associated with lower risk of SLE mortality, especially renal insufficiency- and other organ involvement-related death. The protective effects for survival might be augmented by adherence and full dosage of these drugs.
引用
- Jin Z, Wang F, Pan W, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33099642. doi:10.1093/rheumatology/keaa485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。